PlainRecalls
FDA Drug Moderate Class II Terminated

Florbetaben F-18 (Neuraceq¿) Injection Solution 1.4 to 135 mCi/mL, 50 mL in 1 multi-dose glass vial, Diagnostic-For Intravenous Use Only, Manufactured by SOFIE Co dba SOFIE, Dulles, VA 20166 for Life Molecular Imagining Ltd., NDC 54828-001-50

Reported: October 4, 2023 Initiated: August 22, 2023 #D-1177-2023

Product Description

Florbetaben F-18 (Neuraceq¿) Injection Solution 1.4 to 135 mCi/mL, 50 mL in 1 multi-dose glass vial, Diagnostic-For Intravenous Use Only, Manufactured by SOFIE Co dba SOFIE, Dulles, VA 20166 for Life Molecular Imagining Ltd., NDC 54828-001-50

Reason for Recall

Lack of Assurance of Sterility: out-of-specification test results observed for Filter Integrity Test (FIT).

Details

Recalling Firm
Sofie Co dba Sofie
Units Affected
6 patient doses
Distribution
Product was released to one facility in VA.
Location
Sterling, VA

Frequently Asked Questions

What product was recalled?
Florbetaben F-18 (Neuraceq¿) Injection Solution 1.4 to 135 mCi/mL, 50 mL in 1 multi-dose glass vial, Diagnostic-For Intravenous Use Only, Manufactured by SOFIE Co dba SOFIE, Dulles, VA 20166 for Life Molecular Imagining Ltd., NDC 54828-001-50. Recalled by Sofie Co dba Sofie. Units affected: 6 patient doses.
Why was this product recalled?
Lack of Assurance of Sterility: out-of-specification test results observed for Filter Integrity Test (FIT).
Which agency issued this recall?
This recall was issued by the FDA Drug on October 4, 2023. Severity: Moderate. Recall number: D-1177-2023.